HRAS MUTATIONS OR PERIPHERAL T CELL LYMPHOMA (PTCL)

Clinical trials for HRAS MUTATIONS OR PERIPHERAL T CELL LYMPHOMA (PTCL) explained in plain language.

Never miss a new study

Get alerted when new HRAS MUTATIONS OR PERIPHERAL T CELL LYMPHOMA (PTCL) trials appear

Sign up with your email to follow new studies for HRAS MUTATIONS OR PERIPHERAL T CELL LYMPHOMA (PTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Experimental drug made available for patients with no other options

Disease control AVAILABLE

This program provides single-patient access to tipifarnib, an experimental drug, for adults with HRAS mutations or peripheral T-cell lymphoma (PTCL) who have exhausted standard treatments and cannot join other clinical trials. The goal is to offer a potential treatment when no sa…

Matched conditions: HRAS MUTATIONS OR PERIPHERAL T CELL LYMPHOMA (PTCL)

Sponsor: Kura Oncology, Inc. • Aim: Disease control

Last updated Jul 01, 2026 00:00 UTC

HRAS MUTATIONS OR PERIPHERAL T CELL LYMPHOMA (PTCL)

Get alerted when new HRAS MUTATIONS OR PERIPHERAL T CELL LYMPHOMA (PTCL) trials appear

Experimental drug made available for patients with no other options